<ul><li>Gilead's Trodelvy, in combination with Keytruda, reduced the risk of advanced triple-negative breast cancer progression by 35% in a trial.</li><li>Patients on Trodelvy and Keytruda had longer progression-free survival compared to those on standard chemotherapy and Keytruda.</li><li>The study results suggest that the Trodelvy/Keytruda combination could become a new front-line standard of care for patients with advanced triple-negative breast cancer.</li><li>The side effects of Trodelvy included neutropenia and diarrhea, with ongoing studies exploring its use as an initial treatment for triple-negative breast cancer patients.</li></ul>

Breast cancer treatment: Gilead’s Trodelvy, with Keytruda, cuts disease’s risk by 35% in trial

Discover more